LakeShore Biopharma Co Overview
LakeShore Biopharma Co (LSB) has a P/E ratio of -0.48, below the sector sector average of 47.3.
Get informed when a big investor buys or sells
+ Follow-0.48
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for LSB is -0.48. That is below the sector sector average of 47.3. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, LSB currently prints -0.48 for P/E ratio, while the sector average sits near 47.3. That is roughly 101.0% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.
A P/E ratio of -0.48 for LakeShore Biopharma Co is not 'good' or 'bad' on its own. Compare it with the peer average (47.3) and with LSB's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting LSB's P/E ratio (-0.48), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
